Abstract:
:Patients with coronary artery disease (CAD) commonly have varying degrees of coexisting cerebrovascular disease (CVD) and chronic kidney disease (CKD), and proper management is complicated partly because of a lack of unifying guidelines. The aim of this article is to review the current literature and propose the optimal treatment regimen in patients with all three disease states. Angiotensin-converting enzyme inhibitors (ACE-I) should be universally administered. High-dose statin therapy to reach a target low-density lipoprotein (LDL) of 70-100 mg/dL is advocated, although patients with a history of cerebral bleeding must be carefully monitored for possible recurrence. Beta-blockers are appropriate after a recent coronary event, and amlodipine or thiazide diuretics should be used after a recent stroke (within 6 months). Patients with a history of stroke (with or without coexisting CAD and CKD) should receive aspirin (75-150 mg/day) indefinitely. Clopidogrel or aspirin plus extended-release dipyridamole (ER-DP) may be prescribed in patients allergic or resistant to aspirin. If stroke is attributable to cardiogenic embolism, anticoagulation is indicated. In patients with acute coronary syndromes (ACS) (excluding ST-elevated myocardial infarct) who undergo percutaneous coronary intervention (PCI), aspirin plus clopidogrel is indicated for secondary prevention for up to 12 months. There are no data supporting the use of aspirin plus clopidogrel in patients with CKD who develop ACS. Aspirin plus clopidogrel is contraindicated for stroke prevention.
journal_name
Cardiovasc Therjournal_title
Cardiovascular therapeuticsauthors
Notaro LA,Usman MH,Burke JF,Siddiqui A,Superdock KR,Ezekowitz MDdoi
10.1111/j.1755-5922.2009.00087.xsubject
Has Abstractpub_date
2009-10-01 00:00:00pages
199-215issue
3eissn
1755-5914issn
1755-5922pii
CDR087journal_volume
27pub_type
杂志文章,评审abstract:Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1155/2021/8836450
更新日期:2021-01-13 00:00:00
abstract:Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1155/2019/9482797
更新日期:2019-04-01 00:00:00
abstract:INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,meta分析,评审
doi:10.1111/1755-5922.12176
更新日期:2016-04-01 00:00:00
abstract:INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spani...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,多中心研究
doi:10.1111/1755-5922.12237
更新日期:2017-04-01 00:00:00
abstract:INTRODUCTION:Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. AIMS:We sought to evaluate the safety and cl...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12111
更新日期:2015-04-01 00:00:00
abstract::Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/j.1755-5922.2008.00070.x
更新日期:2009-04-01 00:00:00
abstract:BACKGROUND:The systematic review and meta-analysis are to evaluate the effect of t Telmisartan on atrial fibrillation (AF) recurrences in hypertensive patients with paroxysmal AF. METHODS:MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. Random controlled trials (RCTs) were conduct...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,meta分析,评审
doi:10.1111/1755-5922.12073
更新日期:2014-08-01 00:00:00
abstract::Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to b...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/j.1755-5922.2009.00105.x
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12458
更新日期:2018-10-01 00:00:00
abstract:INTRODUCTION:Rap1, a member of Ras superfamily of small GTP-binding proteins, is involved in cardiovascular biology in numerous ways. It is an evolutionary conserved regulator of adhesion, polarity, differentiation and growth. AIMS:Our aim was to analyze Rap1-activated rat bone marrow mesenchymal stem cells (MSCs) for...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12248
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12027
更新日期:2013-12-01 00:00:00
abstract:AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12085
更新日期:2014-10-01 00:00:00
abstract::Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/1755-5922.12090
更新日期:2014-10-01 00:00:00
abstract:AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/1755-5922.12327
更新日期:2018-06-01 00:00:00
abstract::This study aimed to investigate the correlation between complement C1q tumor necrosis factor-related protein 1 (CTRP1) and subclinical target organ damage (STOD) in essential hypertension (EH). 720 patients were enrolled in this study, including 360 healthy subjects and 360 patients with EH. The EH group included 183 ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1155/2019/4183781
更新日期:2019-06-02 00:00:00
abstract::Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages play a crucial role in the occurrence and ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/1755-5922.12436
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/j.1755-5922.2010.00203.x
更新日期:2011-08-01 00:00:00
abstract:OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to t...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/j.1755-5922.2011.00264.x
更新日期:2012-08-01 00:00:00
abstract::The pericardium is composed of visceral and parietal components. In view of the pericardium's simple structure, pathologic processes involving it are understandably few. However, despite a limited number of clinical syndromes, the pericardium is affected by virtually every category of disease, including infectious, ne...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/j.1755-5922.2010.00151.x
更新日期:2011-10-01 00:00:00
abstract::Prediabetes is an intermediate hyperglycaemic state which has been associated with cardiovascular dysfunction. However, cardiovascular dysfunction is not only caused by intermediate hyperglycaemia but also endothelial dysfunction, inflammation, and oxidative stress associated with prediabetes. Bredemolic acid (BA), an...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1155/2020/1936406
更新日期:2020-02-11 00:00:00
abstract:AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12178
更新日期:2016-06-01 00:00:00
abstract::In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/j.1755-5922.2010.00214.x
更新日期:2011-06-01 00:00:00
abstract:OBJECTIVES:Inflammation after myocardial infarction (MI) causes cardiac nerve sprouting and consequent ventricular arrhythmias (VAs). Macrophages, as major immune cells, are involved in the entire inflammation response process and serve as a link between inflammation and sympathetic hyperinnervation by regulating nerve...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12193
更新日期:2016-08-01 00:00:00
abstract:BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1111/j.1755-5922.2011.00297.x
更新日期:2013-04-01 00:00:00
abstract:AIMS:Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS:In a prosp...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,多中心研究
doi:10.1111/1755-5922.12270
更新日期:2017-08-01 00:00:00
abstract::Thiazide diuretics are one of the most widely used and cost-effective classes of antihypertensive agents worldwide. Thiazides however have a significant side effect profile and are frequently insufficient to normalize blood pressure alone. Thiazide-induced hyponatraemia (TIH) is a major adverse effect, affecting up to...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章,评审
doi:10.1111/j.1755-5922.2011.00286.x
更新日期:2012-10-01 00:00:00
abstract:AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12046
更新日期:2013-12-01 00:00:00
abstract:INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12281
更新日期:2017-10-01 00:00:00
abstract:BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12277
更新日期:2017-10-01 00:00:00
abstract:INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...
journal_title:Cardiovascular therapeutics
pub_type: 杂志文章
doi:10.1111/1755-5922.12469
更新日期:2018-12-01 00:00:00